Eisai Full Year 2025 Earnings: Beats Expectations

Eisai (TSE:4523) Full Year 2025 Results

Key Financial Results

• Revenue: JP¥789.4b (up 6.4% from FY 2024).
• Net income: JP¥46.4b (up 9.5% from FY 2024).
• Profit margin: 5.9% (up from 5.7% in FY 2024). The increase in margin was driven by higher revenue.
• EPS: JP¥164 (up from JP¥148 in FY 2024).

We've discovered 1 warning sign about Eisai. View them for free.

4523 Post-Clinical Trial Products

• Launched (during full year): 12.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eisai Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 2.8%.

The primary driver behind last 12 months revenue was the Pharmaceutical Business - Americas segment contributing a total revenue of JP¥278.3b (35% of total revenue). The largest operating expense was General & Administrative costs, amounting to JP¥405.9b (71% of total expenses). Explore how 4523's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are down 7.9% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Eisai that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.